Gene variant may explain why some People's 'Good' cholesterol works better
NCT ID NCT03109067
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how a common gene variation (TaqIB) affects the function of HDL, or 'good' cholesterol, after a meal. Researchers compared two groups of healthy men with different versions of this gene to see how well their HDL could remove cholesterol from cells. The goal was to better understand why some people are more protected from heart disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help explain why some people have better heart protection from HDL cholesterol, potentially guiding future personalized prevention strategies.
- What could go wrong
- This is a small, completed observational study in healthy men only. It does not test a treatment, so it cannot directly lead to a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Sep 2011
- Finished
-
Nov 2015
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Affiliation to a national social security scheme 2. Age between 18 and 60 years old 3. Male subjects 4. Participants harboring either a B2 (genotype AA) allele or a B1 (genotype GG) in TaqIB polymorphism of CETP gene 5. Fasted plasmatic triglyceridemia \< 300 mg/dL 6. Free prior and informed written consent given by the participant Exclusion Criteria: 1. Participants with an history of symptomatic cardio-vascular disease (infarct, angina pectoris, acute coronary syndrome, cardiac surgery, endoluminal coronal intervention, stroke, symptomatic peripheral artery disease) within 6 months prior to inclusion. 2. Triglyceridemia \> 3 g/L 3. Participants having other lipid-lowering agents than statin (fibrate, niacin, ezetimibe) 4. Participants having a treatment (either systemic or local) which might interfere with the evaluation of study parameters. 5. Excessive alcohol consumption, or any drug addiction. An excessive alcohol consumption is superior to 21 time 30 mL of alcohol or 120 mL of wine or 355 mL of beer. 6. Regular smoker or smoking cessation within the last year 7. Significant abnormality on the full blood count or plasmatic and urinary biochemistry analysis. 8. Chronic or acute disease either life threatening or able to modify study results, including among others : 1. Diabetes 2. Renal diseases : nephrotic syndrome, chronic kidney failure and/or creatininemia \> 1.7 time the upper limit of normal (ULN). 3. Hypothyroidism defined by thyroid-stimulating hormone \> 2x ULN 4. Hepatobiliary disease or viral hepatitis B or C confirmed by transaminases \> 2x ULN or alkaline phosphatase \> 1.5x ULN or total bilirubinemia \> 1.5x ULN at screening. 5. Known HIV 6. Gastro-intestinal disorder or disease that might modify intestinal absorption, bariatric surgery. 9. Participant who might interfere with the quality of the study or might compromise the study according to the investigator. 10. Participant currently enrolled in another study or in the exclusion period of another study. 11. Participants with uncontrolled hypertension defined by a systolic blood pressure \> 140 mmHg or a diastolic blood pressure \> 90 mmHg. 12. Participants with a C reactive protein (CRP) \> 5mg/L 13. Participants with a E2/E2 phenotype of apolipoprotein E. 14. Blood donation or product derived-from blood donation within the last 3 months prior to the test meal.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre d'Investigation Clinique Paris Est
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?
- New injection MWN117 tested for safety in obesity
- Can a new drug avoid the high? soticlestat put to the test
- Liver trouble changes how drugs work: scientists test soticlestat
- Can a hard cycling sprint change a Heart-Calming peptide?